{"gene":"ZNF521","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":2003,"finding":"EHZF (ZNF521) complexes with SMADs 1 and 4 in response to BMPs and binds to a BMP2/4-responsive element, enhancing its transcriptional activity; EHZF also inhibits the transcriptional activity of Early B-cell Factor (EBF1).","method":"Co-immunoprecipitation (SMAD complex), transcriptional reporter assay (BMP2/4 responsive element), transactivation assay (EBF inhibition)","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional assays (co-IP + reporter) in single lab with two orthogonal methods","pmids":["14630787"],"is_preprint":false},{"year":2002,"finding":"Evi3 (ZNF521/mouse ortholog) protein is nuclear and, like EBFAZ, binds SMAD1 and SMAD4 in response to BMP2 signaling; Evi3 (but not EBFAZ) is expressed in B cells and is proposed to interact with and regulate EBF in B cells.","method":"RT-PCR for expression in B cells, subcellular localization by nuclear detection, and inference from EBFAZ binding data (Co-IP)","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization plus Co-IP evidence from single lab for SMAD interactions; EBF interaction inferred by homology and expression, not direct Co-IP","pmids":["12393497"],"is_preprint":false},{"year":2005,"finding":"Evi3 (ZNF521 mouse ortholog) overexpression in B-cell tumors upregulates EBF target genes (CD19, CD38); the terminal six zinc fingers of Evi3 are required for modulation of EBF activity, as determined by domain-deletion transactivation assays.","method":"Transactivation assay with deletion mutants; reconstitution of primary leukemia cells with surface marker analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-deletion functional assay plus primary cell reconstitution, single lab","pmids":["15580294"],"is_preprint":false},{"year":2010,"finding":"Zfp521 (ZNF521) cooperates with E2A-HLF to promote B-lineage acute lymphoblastic leukemia in mice; retroviral insertion-driven overexpression of Zfp521 specifically results in B-lineage ALL, and double transgenic mice (E2A-HLF + Zfp521) frequently develop B-lineage ALL.","method":"Retroviral insertional mutagenesis screen, inverse PCR, inducible knock-in and transgenic mouse models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with knock-in and transgenic models, replicated in multiple mouse lines","pmids":["20062079"],"is_preprint":false},{"year":2015,"finding":"ZNF521 interacts with the core components of the NuRD (nuclear remodelling and histone deacetylase) complex; additionally, ZNF521 interacts with ZNF423, Spt16, and Spt5 as novel molecular partners.","method":"Cross-linking co-immunoprecipitation followed by shotgun proteomics (DSP cross-linker, limited proteolysis, 18O labeling, Western blotting validation)","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative MS interactome with Western blot validation, single lab, novel partners confirmed by two orthogonal methods","pmids":["25774781"],"is_preprint":false},{"year":2017,"finding":"MLL-AF9 and MLL-ENL fusion proteins directly bind to the ZNF521 promoter and activate its transcription; ZNF521 knockdown in MLL-rearranged AML lines causes decreased proliferation, reduced colony formation, cell cycle arrest, and induction of myeloid differentiation with loss of the MLL-AF9 leukemic gene signature.","method":"ChIP (MLL fusion protein binding to ZNF521 promoter), shRNA knockdown with proliferation/colony assays, gene expression profiling","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP establishes direct transcriptional regulation; functional KD with multiple orthogonal phenotypic readouts in both cell lines and primary xenograft cells","pmids":["28412732"],"is_preprint":false},{"year":2018,"finding":"ZNF521 inhibits adipogenic differentiation of human adipose-derived stem cells (hADSCs); enforced overexpression delays and reduces adipocyte generation, while ZNF521 silencing enhances adipogenesis; this inhibition is at least partly mediated by suppression of EBF1 and inhibition of ZNF423 expression.","method":"Lentiviral overexpression and RNAi silencing in hADSCs, adipocyte differentiation assays, molecular marker quantification","journal":"Stem cell reviews and reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with defined molecular pathway placement (EBF1, ZNF423), single lab","pmids":["29938352"],"is_preprint":false},{"year":2018,"finding":"ZNF521 represses osteoblastic differentiation in hADSCs; enforced ZNF521 expression reduces osteoblast markers (collagen I, alkaline phosphatase, osterix, osteopontin, calcium deposits), while ZNF521 silencing significantly enhances early osteogenic markers and matrix mineralization.","method":"Lentiviral overexpression and RNAi silencing in hADSCs, osteogenic differentiation assays with morphological and molecular readouts","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple osteogenic markers, single lab","pmids":["30567301"],"is_preprint":false},{"year":2019,"finding":"ZNF521 physically interacts with GLI1 and GLI2 (Sonic Hedgehog pathway transcriptional effectors) and enhances their transcriptional activity on GLI-responsive promoters; this synergism requires the N-terminal NuRD-binding motif of ZNF521 and is sensitive to HDAC and GLI inhibitors.","method":"Co-immunoprecipitation (ZNF521-GLI1/GLI2), luciferase reporter assays on GLI-responsive promoters, domain deletion (N-terminal motif), pharmacological inhibition (HDAC, GLI inhibitors)","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus reporter assays with domain-deletion and pharmacological validation, multiple orthogonal methods in single rigorous study","pmids":["31558698"],"is_preprint":false},{"year":2020,"finding":"ZNF521 inhibits HCC cell proliferation and colony formation through transcriptional repression of Runx2 and inactivation of the AKT phosphorylation pathway.","method":"ZNF521 overexpression/silencing in HCC cells, proliferation and colony assays, Western blotting for Runx2 and pAKT","journal":"Journal of Cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, functional assays but limited mechanistic detail on direct Runx2 regulation; abstract does not describe ChIP or direct binding evidence","pmids":["32913476"],"is_preprint":false},{"year":2022,"finding":"ZNF521 suppresses EBF1 expression, and EBF1 directly represses AKR1B1 transcription (shown by luciferase reporter and ChIP); ZNF521 knockdown induces EBF1 expression, which suppresses AKR1B1 and attenuates gastric cancer cell proliferation, migration, and invasion.","method":"shRNA knockdown of ZNF521, luciferase reporter assay and ChIP for EBF1-AKR1B1 promoter interaction, qRT-PCR, Western blotting, CCK-8, wound healing, transwell assays","journal":"The Kaohsiung journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays establish direct EBF1-AKR1B1 regulatory axis; ZNF521-EBF1 link demonstrated by rescue experiment, single lab","pmids":["36397644"],"is_preprint":false},{"year":2024,"finding":"ZNF521 interacts with HDAC8, which deacetylates SMC3; ZNF521 promotes leukemic cell proliferation by reducing SMC3 expression and acetylation through HDAC8; knockdown of ZNF521 upregulates SMC3 acetylation and downregulates HDAC8, CDK2, and CDK6, causing cell cycle arrest at G2/M and promoting apoptosis.","method":"Co-immunoprecipitation (ZNF521-HDAC8 interaction), shRNA knockdown, HDAC8 inhibitor treatment, Western blotting for SMC3 expression/acetylation, cell cycle and apoptosis assays","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishes ZNF521-HDAC8 interaction; functional rescue and inhibitor experiments confirm pathway, single lab","pmids":["39309877"],"is_preprint":false},{"year":2014,"finding":"RNAi-mediated silencing of ZNF521 in primary chondrocytes significantly alters the COL2A1/COL1A1 expression ratio, a marker of the differentiated chondrocyte phenotype, indicating ZNF521 regulates chondrocyte homeostasis.","method":"RNAi silencing in primary chondrocytes cultured in alginate beads, gene expression analysis","journal":"Mediators of inflammation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-method knockdown with gene expression readout, no mechanistic pathway placement, single lab","pmids":["24976683"],"is_preprint":false},{"year":2025,"finding":"CRISPRi knockdown of ZNF521 in hPSC-derived organoids causes ectopic neural tube closure points in an anterior neurulation model, identifying ZNF521 as a negative regulator (preventer) of ectopic closure during anterior neural tube morphogenesis; single-cell transcriptomics revealed ZNF521 has an opposing regulatory role to ZIC2 and SOX11 in a gene regulatory program governing neural tube closure.","method":"Arrayed CRISPRi screening in hPSC-derived anterior neurulation organoids, single-cell transcriptomics","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single-gene CRISPRi knockdown with morphological and transcriptomic readouts, no biochemical mechanism defined","pmids":["bio_10.1101_2025.07.21.665862"],"is_preprint":true}],"current_model":"ZNF521 is a multi-zinc-finger transcription co-factor that: (1) binds SMAD1/4 to enhance BMP-responsive transcription; (2) inhibits EBF1 activity through its C-terminal zinc fingers, thereby blocking B-lymphoid differentiation; (3) physically interacts with the NuRD complex via its N-terminal motif, which is required for its cooperative enhancement of GLI1/GLI2-driven Hedgehog transcription; (4) interacts with HDAC8 to suppress SMC3 acetylation, promoting leukemic proliferation; (5) is transcriptionally activated by MLL fusion oncoproteins to sustain a differentiation block in AML; and (6) inhibits both adipogenic and osteoblastic differentiation of mesenchymal progenitors, in part through repression of EBF1 and ZNF423."},"narrative":{"mechanistic_narrative":"ZNF521 is a multi-zinc-finger nuclear transcription co-factor that controls the differentiation state of hematopoietic and mesenchymal progenitors by partnering with sequence-specific transcription factors and chromatin-modifying complexes [PMID:14630787, PMID:25774781]. In BMP signaling it complexes with SMAD1 and SMAD4 to bind a BMP2/4-responsive element and enhance BMP-driven transcription, while through its terminal six zinc fingers it inhibits the B-cell determinant EBF1, thereby restraining B-lymphoid differentiation [PMID:14630787, PMID:15580294]. ZNF521 associates with the NuRD chromatin-remodeling/deacetylase complex via an N-terminal motif, and this NuRD-binding motif is required for its cooperative enhancement of GLI1/GLI2-driven Hedgehog transcription [PMID:25774781, PMID:31558698]; consistent with a deacetylase-coupled mechanism, ZNF521 also binds HDAC8 to lower SMC3 acetylation and sustain leukemic proliferation [PMID:39309877]. In leukemogenesis ZNF521 acts as an oncogenic effector: it cooperates with E2A-HLF to drive B-lineage ALL, and its promoter is directly bound and activated by MLL-AF9/MLL-ENL fusions to maintain a myeloid differentiation block, such that its loss triggers cell-cycle arrest and myeloid maturation [PMID:20062079, PMID:28412732, PMID:39309877]. Beyond blood, ZNF521 represses both adipogenic and osteoblastic differentiation of mesenchymal stem cells, partly through suppression of EBF1 and ZNF423 [PMID:29938352, PMID:30567301].","teleology":[{"year":2002,"claim":"Established that the ZNF521 protein (Evi3/EHZF) is nuclear and links BMP signaling to B-cell regulation, framing it as a candidate SMAD-associated factor.","evidence":"Nuclear localization, RT-PCR expression in B cells, and Co-IP of SMAD1/SMAD4 in mouse ortholog","pmids":["12393497"],"confidence":"Medium","gaps":["EBF interaction inferred by homology, not directly shown","No domain mapping of SMAD interaction"]},{"year":2003,"claim":"Defined ZNF521's dual transcriptional role: it potentiates BMP/SMAD-responsive transcription while inhibiting EBF1, positioning it at a node controlling B-lymphoid commitment.","evidence":"Co-IP of SMAD1/4, BMP2/4-responsive reporter assays, and EBF transactivation assays in human cells","pmids":["14630787"],"confidence":"Medium","gaps":["Direct DNA binding by ZNF521 not demonstrated","Mechanism of EBF1 inhibition undefined"]},{"year":2005,"claim":"Localized the EBF-modulating activity to the terminal six zinc fingers and connected it to a B-cell oncogenic output.","evidence":"Domain-deletion transactivation assays and primary leukemia cell reconstitution with surface marker analysis (mouse ortholog)","pmids":["15580294"],"confidence":"Medium","gaps":["No structural basis for zinc-finger/EBF contact","Single ortholog system"]},{"year":2010,"claim":"Demonstrated in vivo oncogenic cooperation, showing ZNF521 overexpression collaborates with E2A-HLF to specifically drive B-lineage ALL.","evidence":"Retroviral insertional mutagenesis, inducible knock-in and transgenic mouse models","pmids":["20062079"],"confidence":"High","gaps":["Molecular mechanism of cooperation with E2A-HLF not resolved","Target genes downstream of the block not mapped"]},{"year":2014,"claim":"Extended ZNF521 function to non-hematopoietic differentiation by implicating it in chondrocyte phenotype maintenance.","evidence":"RNAi silencing in primary chondrocytes with COL2A1/COL1A1 ratio readout","pmids":["24976683"],"confidence":"Low","gaps":["Single-method knockdown with no mechanistic pathway placement","No direct target identified"]},{"year":2015,"claim":"Defined the chromatin machinery ZNF521 operates through by identifying NuRD core components, ZNF423, Spt16, and Spt5 as physical partners.","evidence":"Cross-linking Co-IP with shotgun proteomics and Western blot validation","pmids":["25774781"],"confidence":"Medium","gaps":["Interaction interfaces not mapped","Functional consequence of each partner not tested here"]},{"year":2017,"claim":"Placed ZNF521 downstream of MLL fusion oncoproteins, showing it is a direct transcriptional target sustaining the AML differentiation block.","evidence":"ChIP of MLL-AF9/MLL-ENL at the ZNF521 promoter, shRNA knockdown with proliferation/colony/differentiation and expression profiling","pmids":["28412732"],"confidence":"High","gaps":["Direct downstream targets of ZNF521 in AML not defined","Co-factor dependence of the block not dissected"]},{"year":2018,"claim":"Established ZNF521 as a brake on mesenchymal differentiation along both adipogenic and osteogenic lineages, acting via EBF1 and ZNF423 repression.","evidence":"Reciprocal lentiviral overexpression and RNAi in hADSCs with differentiation assays and marker quantification","pmids":["29938352","30567301"],"confidence":"Medium","gaps":["Direct vs indirect repression of EBF1/ZNF423 not separated","Chromatin occupancy at these loci not shown"]},{"year":2019,"claim":"Connected ZNF521 to Hedgehog signaling and mechanistically tied its co-activator function to NuRD recruitment.","evidence":"Reciprocal Co-IP with GLI1/GLI2, GLI-responsive luciferase reporters, N-terminal motif deletion, and HDAC/GLI pharmacological inhibition","pmids":["31558698"],"confidence":"High","gaps":["How NuRD recruitment activates rather than represses GLI targets unresolved","No genome-wide GLI/ZNF521 co-occupancy"]},{"year":2020,"claim":"Reported a context-dependent tumor-suppressive role in hepatocellular carcinoma via Runx2 repression and AKT inactivation.","evidence":"ZNF521 overexpression/silencing in HCC cells with proliferation/colony assays and Western blot for Runx2 and pAKT","pmids":["32913476"],"confidence":"Low","gaps":["No ChIP or direct Runx2 binding evidence","Link between Runx2 and AKT pathway not mechanistically established"]},{"year":2022,"claim":"Defined a ZNF521→EBF1→AKR1B1 axis explaining how ZNF521 promotes gastric cancer progression.","evidence":"shRNA knockdown, luciferase reporter and ChIP for EBF1-AKR1B1 promoter, with migration/invasion assays","pmids":["36397644"],"confidence":"Medium","gaps":["Direct ZNF521 binding at EBF1 not shown","Generality of axis beyond gastric cancer untested"]},{"year":2024,"claim":"Identified an HDAC8/SMC3 deacetylation mechanism by which ZNF521 drives leukemic proliferation.","evidence":"Co-IP of ZNF521-HDAC8, shRNA knockdown, HDAC8 inhibition, SMC3 acetylation Western blots, cell cycle and apoptosis assays","pmids":["39309877"],"confidence":"Medium","gaps":["Whether ZNF521 recruits HDAC8 to specific loci unknown","Direct vs indirect control of CDK2/CDK6 unresolved"]},{"year":2025,"claim":"Implicated ZNF521 in early neural morphogenesis as a negative regulator of ectopic neural tube closure.","evidence":"Arrayed CRISPRi screen in hPSC-derived anterior neurulation organoids with single-cell transcriptomics (preprint)","pmids":["bio_10.1101_2025.07.21.665862"],"confidence":"Low","gaps":["Preprint, no biochemical mechanism","Relationship to ZIC2/SOX11 program correlative"]},{"year":null,"claim":"How ZNF521 toggles between co-activation (BMP/SMAD, GLI) and repression (EBF1, ZNF423, Runx2), and whether this reflects locus-specific recruitment of NuRD/HDAC versus distinct partner sets, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No genome-wide DNA-binding/occupancy map","Determinants of activator vs repressor mode unknown","No structural model of zinc-finger/partner contacts"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,8,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,5]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,11]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,11]}],"complexes":["NuRD complex"],"partners":["SMAD1","SMAD4","EBF1","ZNF423","GLI1","GLI2","HDAC8","SUPT16H"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96K83","full_name":"Zinc finger protein 521","aliases":["Early hematopoietic zinc finger protein","LYST-interacting protein 3"],"length_aa":1311,"mass_kda":147.9,"function":"Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signaling and in the regulation of the immature compartment of the hematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes. Acts as a transcriptional repressor via its interaction with EBF1, a transcription factor involved specification of B-cell lineage; this interaction preventing EBF1 to bind DNA and activate target genes","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q96K83/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF521","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HDAC2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF521","total_profiled":1310},"omim":[{"mim_id":"610974","title":"ZINC FINGER PROTEIN 521; ZNF521","url":"https://www.omim.org/entry/610974"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":59.3}],"url":"https://www.proteinatlas.org/search/ZNF521"},"hgnc":{"alias_symbol":["EHZF","Evi3"],"prev_symbol":[]},"alphafold":{"accession":"Q96K83","domains":[{"cath_id":"-","chopping":"695-833","consensus_level":"medium","plddt":70.9888,"start":695,"end":833},{"cath_id":"3.30.160.60","chopping":"907-913_927-1044","consensus_level":"medium","plddt":70.4534,"start":907,"end":1044},{"cath_id":"-","chopping":"1256-1297","consensus_level":"medium","plddt":55.5374,"start":1256,"end":1297}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96K83","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96K83-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96K83-F1-predicted_aligned_error_v6.png","plddt_mean":60.78},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF521","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF521"},"sequence":{"accession":"Q96K83","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96K83.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96K83/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96K83"}},"corpus_meta":[{"pmid":"14630787","id":"PMC_14630787","title":"Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630787","citation_count":75,"is_preprint":false},{"pmid":"12393497","id":"PMC_12393497","title":"Evi3, a common retroviral integration site in murine B-cell lymphoma, encodes an EBFAZ-related Krüppel-like zinc finger protein.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393497","citation_count":56,"is_preprint":false},{"pmid":"20062079","id":"PMC_20062079","title":"Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20062079","citation_count":38,"is_preprint":false},{"pmid":"8107195","id":"PMC_8107195","title":"Identification of Evi-3, a novel common site of retroviral integration in mouse AKXD B-cell lymphomas.","date":"1994","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8107195","citation_count":38,"is_preprint":false},{"pmid":"15580294","id":"PMC_15580294","title":"Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15580294","citation_count":28,"is_preprint":false},{"pmid":"31558698","id":"PMC_31558698","title":"The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31558698","citation_count":27,"is_preprint":false},{"pmid":"26788497","id":"PMC_26788497","title":"ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26788497","citation_count":25,"is_preprint":false},{"pmid":"30567301","id":"PMC_30567301","title":"ZNF521 Represses Osteoblastic Differentiation in Human Adipose-Derived Stem Cells.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30567301","citation_count":24,"is_preprint":false},{"pmid":"29938352","id":"PMC_29938352","title":"ZNF521 Has an Inhibitory Effect on the Adipogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells.","date":"2018","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/29938352","citation_count":23,"is_preprint":false},{"pmid":"34445164","id":"PMC_34445164","title":"Regulatory Role of microRNAs Targeting the Transcription Co-Factor ZNF521 in Normal Tissues and Cancers.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445164","citation_count":22,"is_preprint":false},{"pmid":"25774781","id":"PMC_25774781","title":"Validation of a novel shotgun proteomic workflow for the discovery of protein-protein interactions: focus on ZNF521.","date":"2015","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/25774781","citation_count":22,"is_preprint":false},{"pmid":"24976683","id":"PMC_24976683","title":"Expression profiling and functional implications of a set of zinc finger proteins, ZNF423, ZNF470, ZNF521, and ZNF780B, in primary osteoarthritic articular chondrocytes.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24976683","citation_count":21,"is_preprint":false},{"pmid":"28412727","id":"PMC_28412727","title":"ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28412727","citation_count":18,"is_preprint":false},{"pmid":"36397644","id":"PMC_36397644","title":"ZNF521/EBF1 axis regulates AKR1B1 to promote the proliferation, migration, and invasion of gastric cancer cells.","date":"2022","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36397644","citation_count":13,"is_preprint":false},{"pmid":"32913476","id":"PMC_32913476","title":"ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32913476","citation_count":13,"is_preprint":false},{"pmid":"36191006","id":"PMC_36191006","title":"Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36191006","citation_count":8,"is_preprint":false},{"pmid":"39309877","id":"PMC_39309877","title":"ZNF521 promotes acute myeloid leukemogenesis by suppressing the expression and acetylation of SMC3.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39309877","citation_count":3,"is_preprint":false},{"pmid":"39436449","id":"PMC_39436449","title":"Exploring the contribution of Zfp521/ZNF521 on primary hematopoietic stem/progenitor cells and leukemia progression.","date":"2024","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/39436449","citation_count":2,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.21.665862","title":"Arrayed single-gene perturbations identify drivers of human anterior neural tube closure","date":"2025-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.21.665862","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.01.626271","title":"Abnormal eNK cells contribute to endometrial fibrosis in intrauterine adhesions patients","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.626271","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11542,"output_tokens":3483,"usd":0.043436,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11040,"output_tokens":3944,"usd":0.0769,"stage2_stop_reason":"end_turn"},"total_usd":0.120336,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"EHZF (ZNF521) complexes with SMADs 1 and 4 in response to BMPs and binds to a BMP2/4-responsive element, enhancing its transcriptional activity; EHZF also inhibits the transcriptional activity of Early B-cell Factor (EBF1).\",\n      \"method\": \"Co-immunoprecipitation (SMAD complex), transcriptional reporter assay (BMP2/4 responsive element), transactivation assay (EBF inhibition)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional assays (co-IP + reporter) in single lab with two orthogonal methods\",\n      \"pmids\": [\"14630787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Evi3 (ZNF521/mouse ortholog) protein is nuclear and, like EBFAZ, binds SMAD1 and SMAD4 in response to BMP2 signaling; Evi3 (but not EBFAZ) is expressed in B cells and is proposed to interact with and regulate EBF in B cells.\",\n      \"method\": \"RT-PCR for expression in B cells, subcellular localization by nuclear detection, and inference from EBFAZ binding data (Co-IP)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization plus Co-IP evidence from single lab for SMAD interactions; EBF interaction inferred by homology and expression, not direct Co-IP\",\n      \"pmids\": [\"12393497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Evi3 (ZNF521 mouse ortholog) overexpression in B-cell tumors upregulates EBF target genes (CD19, CD38); the terminal six zinc fingers of Evi3 are required for modulation of EBF activity, as determined by domain-deletion transactivation assays.\",\n      \"method\": \"Transactivation assay with deletion mutants; reconstitution of primary leukemia cells with surface marker analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-deletion functional assay plus primary cell reconstitution, single lab\",\n      \"pmids\": [\"15580294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Zfp521 (ZNF521) cooperates with E2A-HLF to promote B-lineage acute lymphoblastic leukemia in mice; retroviral insertion-driven overexpression of Zfp521 specifically results in B-lineage ALL, and double transgenic mice (E2A-HLF + Zfp521) frequently develop B-lineage ALL.\",\n      \"method\": \"Retroviral insertional mutagenesis screen, inverse PCR, inducible knock-in and transgenic mouse models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with knock-in and transgenic models, replicated in multiple mouse lines\",\n      \"pmids\": [\"20062079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZNF521 interacts with the core components of the NuRD (nuclear remodelling and histone deacetylase) complex; additionally, ZNF521 interacts with ZNF423, Spt16, and Spt5 as novel molecular partners.\",\n      \"method\": \"Cross-linking co-immunoprecipitation followed by shotgun proteomics (DSP cross-linker, limited proteolysis, 18O labeling, Western blotting validation)\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative MS interactome with Western blot validation, single lab, novel partners confirmed by two orthogonal methods\",\n      \"pmids\": [\"25774781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MLL-AF9 and MLL-ENL fusion proteins directly bind to the ZNF521 promoter and activate its transcription; ZNF521 knockdown in MLL-rearranged AML lines causes decreased proliferation, reduced colony formation, cell cycle arrest, and induction of myeloid differentiation with loss of the MLL-AF9 leukemic gene signature.\",\n      \"method\": \"ChIP (MLL fusion protein binding to ZNF521 promoter), shRNA knockdown with proliferation/colony assays, gene expression profiling\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP establishes direct transcriptional regulation; functional KD with multiple orthogonal phenotypic readouts in both cell lines and primary xenograft cells\",\n      \"pmids\": [\"28412732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF521 inhibits adipogenic differentiation of human adipose-derived stem cells (hADSCs); enforced overexpression delays and reduces adipocyte generation, while ZNF521 silencing enhances adipogenesis; this inhibition is at least partly mediated by suppression of EBF1 and inhibition of ZNF423 expression.\",\n      \"method\": \"Lentiviral overexpression and RNAi silencing in hADSCs, adipocyte differentiation assays, molecular marker quantification\",\n      \"journal\": \"Stem cell reviews and reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with defined molecular pathway placement (EBF1, ZNF423), single lab\",\n      \"pmids\": [\"29938352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF521 represses osteoblastic differentiation in hADSCs; enforced ZNF521 expression reduces osteoblast markers (collagen I, alkaline phosphatase, osterix, osteopontin, calcium deposits), while ZNF521 silencing significantly enhances early osteogenic markers and matrix mineralization.\",\n      \"method\": \"Lentiviral overexpression and RNAi silencing in hADSCs, osteogenic differentiation assays with morphological and molecular readouts\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple osteogenic markers, single lab\",\n      \"pmids\": [\"30567301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZNF521 physically interacts with GLI1 and GLI2 (Sonic Hedgehog pathway transcriptional effectors) and enhances their transcriptional activity on GLI-responsive promoters; this synergism requires the N-terminal NuRD-binding motif of ZNF521 and is sensitive to HDAC and GLI inhibitors.\",\n      \"method\": \"Co-immunoprecipitation (ZNF521-GLI1/GLI2), luciferase reporter assays on GLI-responsive promoters, domain deletion (N-terminal motif), pharmacological inhibition (HDAC, GLI inhibitors)\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus reporter assays with domain-deletion and pharmacological validation, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"31558698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF521 inhibits HCC cell proliferation and colony formation through transcriptional repression of Runx2 and inactivation of the AKT phosphorylation pathway.\",\n      \"method\": \"ZNF521 overexpression/silencing in HCC cells, proliferation and colony assays, Western blotting for Runx2 and pAKT\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, functional assays but limited mechanistic detail on direct Runx2 regulation; abstract does not describe ChIP or direct binding evidence\",\n      \"pmids\": [\"32913476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF521 suppresses EBF1 expression, and EBF1 directly represses AKR1B1 transcription (shown by luciferase reporter and ChIP); ZNF521 knockdown induces EBF1 expression, which suppresses AKR1B1 and attenuates gastric cancer cell proliferation, migration, and invasion.\",\n      \"method\": \"shRNA knockdown of ZNF521, luciferase reporter assay and ChIP for EBF1-AKR1B1 promoter interaction, qRT-PCR, Western blotting, CCK-8, wound healing, transwell assays\",\n      \"journal\": \"The Kaohsiung journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays establish direct EBF1-AKR1B1 regulatory axis; ZNF521-EBF1 link demonstrated by rescue experiment, single lab\",\n      \"pmids\": [\"36397644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF521 interacts with HDAC8, which deacetylates SMC3; ZNF521 promotes leukemic cell proliferation by reducing SMC3 expression and acetylation through HDAC8; knockdown of ZNF521 upregulates SMC3 acetylation and downregulates HDAC8, CDK2, and CDK6, causing cell cycle arrest at G2/M and promoting apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (ZNF521-HDAC8 interaction), shRNA knockdown, HDAC8 inhibitor treatment, Western blotting for SMC3 expression/acetylation, cell cycle and apoptosis assays\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishes ZNF521-HDAC8 interaction; functional rescue and inhibitor experiments confirm pathway, single lab\",\n      \"pmids\": [\"39309877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RNAi-mediated silencing of ZNF521 in primary chondrocytes significantly alters the COL2A1/COL1A1 expression ratio, a marker of the differentiated chondrocyte phenotype, indicating ZNF521 regulates chondrocyte homeostasis.\",\n      \"method\": \"RNAi silencing in primary chondrocytes cultured in alginate beads, gene expression analysis\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-method knockdown with gene expression readout, no mechanistic pathway placement, single lab\",\n      \"pmids\": [\"24976683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CRISPRi knockdown of ZNF521 in hPSC-derived organoids causes ectopic neural tube closure points in an anterior neurulation model, identifying ZNF521 as a negative regulator (preventer) of ectopic closure during anterior neural tube morphogenesis; single-cell transcriptomics revealed ZNF521 has an opposing regulatory role to ZIC2 and SOX11 in a gene regulatory program governing neural tube closure.\",\n      \"method\": \"Arrayed CRISPRi screening in hPSC-derived anterior neurulation organoids, single-cell transcriptomics\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single-gene CRISPRi knockdown with morphological and transcriptomic readouts, no biochemical mechanism defined\",\n      \"pmids\": [\"bio_10.1101_2025.07.21.665862\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ZNF521 is a multi-zinc-finger transcription co-factor that: (1) binds SMAD1/4 to enhance BMP-responsive transcription; (2) inhibits EBF1 activity through its C-terminal zinc fingers, thereby blocking B-lymphoid differentiation; (3) physically interacts with the NuRD complex via its N-terminal motif, which is required for its cooperative enhancement of GLI1/GLI2-driven Hedgehog transcription; (4) interacts with HDAC8 to suppress SMC3 acetylation, promoting leukemic proliferation; (5) is transcriptionally activated by MLL fusion oncoproteins to sustain a differentiation block in AML; and (6) inhibits both adipogenic and osteoblastic differentiation of mesenchymal progenitors, in part through repression of EBF1 and ZNF423.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF521 is a multi-zinc-finger nuclear transcription co-factor that controls the differentiation state of hematopoietic and mesenchymal progenitors by partnering with sequence-specific transcription factors and chromatin-modifying complexes [#0, #4]. In BMP signaling it complexes with SMAD1 and SMAD4 to bind a BMP2/4-responsive element and enhance BMP-driven transcription, while through its terminal six zinc fingers it inhibits the B-cell determinant EBF1, thereby restraining B-lymphoid differentiation [#0, #2]. ZNF521 associates with the NuRD chromatin-remodeling/deacetylase complex via an N-terminal motif, and this NuRD-binding motif is required for its cooperative enhancement of GLI1/GLI2-driven Hedgehog transcription [#4, #8]; consistent with a deacetylase-coupled mechanism, ZNF521 also binds HDAC8 to lower SMC3 acetylation and sustain leukemic proliferation [#11]. In leukemogenesis ZNF521 acts as an oncogenic effector: it cooperates with E2A-HLF to drive B-lineage ALL, and its promoter is directly bound and activated by MLL-AF9/MLL-ENL fusions to maintain a myeloid differentiation block, such that its loss triggers cell-cycle arrest and myeloid maturation [#3, #5, #11]. Beyond blood, ZNF521 represses both adipogenic and osteoblastic differentiation of mesenchymal stem cells, partly through suppression of EBF1 and ZNF423 [#6, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that the ZNF521 protein (Evi3/EHZF) is nuclear and links BMP signaling to B-cell regulation, framing it as a candidate SMAD-associated factor.\",\n      \"evidence\": \"Nuclear localization, RT-PCR expression in B cells, and Co-IP of SMAD1/SMAD4 in mouse ortholog\",\n      \"pmids\": [\"12393497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"EBF interaction inferred by homology, not directly shown\", \"No domain mapping of SMAD interaction\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined ZNF521's dual transcriptional role: it potentiates BMP/SMAD-responsive transcription while inhibiting EBF1, positioning it at a node controlling B-lymphoid commitment.\",\n      \"evidence\": \"Co-IP of SMAD1/4, BMP2/4-responsive reporter assays, and EBF transactivation assays in human cells\",\n      \"pmids\": [\"14630787\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding by ZNF521 not demonstrated\", \"Mechanism of EBF1 inhibition undefined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Localized the EBF-modulating activity to the terminal six zinc fingers and connected it to a B-cell oncogenic output.\",\n      \"evidence\": \"Domain-deletion transactivation assays and primary leukemia cell reconstitution with surface marker analysis (mouse ortholog)\",\n      \"pmids\": [\"15580294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural basis for zinc-finger/EBF contact\", \"Single ortholog system\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated in vivo oncogenic cooperation, showing ZNF521 overexpression collaborates with E2A-HLF to specifically drive B-lineage ALL.\",\n      \"evidence\": \"Retroviral insertional mutagenesis, inducible knock-in and transgenic mouse models\",\n      \"pmids\": [\"20062079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of cooperation with E2A-HLF not resolved\", \"Target genes downstream of the block not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended ZNF521 function to non-hematopoietic differentiation by implicating it in chondrocyte phenotype maintenance.\",\n      \"evidence\": \"RNAi silencing in primary chondrocytes with COL2A1/COL1A1 ratio readout\",\n      \"pmids\": [\"24976683\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single-method knockdown with no mechanistic pathway placement\", \"No direct target identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the chromatin machinery ZNF521 operates through by identifying NuRD core components, ZNF423, Spt16, and Spt5 as physical partners.\",\n      \"evidence\": \"Cross-linking Co-IP with shotgun proteomics and Western blot validation\",\n      \"pmids\": [\"25774781\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interfaces not mapped\", \"Functional consequence of each partner not tested here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed ZNF521 downstream of MLL fusion oncoproteins, showing it is a direct transcriptional target sustaining the AML differentiation block.\",\n      \"evidence\": \"ChIP of MLL-AF9/MLL-ENL at the ZNF521 promoter, shRNA knockdown with proliferation/colony/differentiation and expression profiling\",\n      \"pmids\": [\"28412732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct downstream targets of ZNF521 in AML not defined\", \"Co-factor dependence of the block not dissected\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established ZNF521 as a brake on mesenchymal differentiation along both adipogenic and osteogenic lineages, acting via EBF1 and ZNF423 repression.\",\n      \"evidence\": \"Reciprocal lentiviral overexpression and RNAi in hADSCs with differentiation assays and marker quantification\",\n      \"pmids\": [\"29938352\", \"30567301\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect repression of EBF1/ZNF423 not separated\", \"Chromatin occupancy at these loci not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected ZNF521 to Hedgehog signaling and mechanistically tied its co-activator function to NuRD recruitment.\",\n      \"evidence\": \"Reciprocal Co-IP with GLI1/GLI2, GLI-responsive luciferase reporters, N-terminal motif deletion, and HDAC/GLI pharmacological inhibition\",\n      \"pmids\": [\"31558698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NuRD recruitment activates rather than represses GLI targets unresolved\", \"No genome-wide GLI/ZNF521 co-occupancy\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reported a context-dependent tumor-suppressive role in hepatocellular carcinoma via Runx2 repression and AKT inactivation.\",\n      \"evidence\": \"ZNF521 overexpression/silencing in HCC cells with proliferation/colony assays and Western blot for Runx2 and pAKT\",\n      \"pmids\": [\"32913476\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ChIP or direct Runx2 binding evidence\", \"Link between Runx2 and AKT pathway not mechanistically established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a ZNF521→EBF1→AKR1B1 axis explaining how ZNF521 promotes gastric cancer progression.\",\n      \"evidence\": \"shRNA knockdown, luciferase reporter and ChIP for EBF1-AKR1B1 promoter, with migration/invasion assays\",\n      \"pmids\": [\"36397644\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ZNF521 binding at EBF1 not shown\", \"Generality of axis beyond gastric cancer untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified an HDAC8/SMC3 deacetylation mechanism by which ZNF521 drives leukemic proliferation.\",\n      \"evidence\": \"Co-IP of ZNF521-HDAC8, shRNA knockdown, HDAC8 inhibition, SMC3 acetylation Western blots, cell cycle and apoptosis assays\",\n      \"pmids\": [\"39309877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZNF521 recruits HDAC8 to specific loci unknown\", \"Direct vs indirect control of CDK2/CDK6 unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated ZNF521 in early neural morphogenesis as a negative regulator of ectopic neural tube closure.\",\n      \"evidence\": \"Arrayed CRISPRi screen in hPSC-derived anterior neurulation organoids with single-cell transcriptomics (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.07.21.665862\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Preprint, no biochemical mechanism\", \"Relationship to ZIC2/SOX11 program correlative\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZNF521 toggles between co-activation (BMP/SMAD, GLI) and repression (EBF1, ZNF423, Runx2), and whether this reflects locus-specific recruitment of NuRD/HDAC versus distinct partner sets, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide DNA-binding/occupancy map\", \"Determinants of activator vs repressor mode unknown\", \"No structural model of zinc-finger/partner contacts\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 8, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 11]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 11]}\n    ],\n    \"complexes\": [\"NuRD complex\"],\n    \"partners\": [\"SMAD1\", \"SMAD4\", \"EBF1\", \"ZNF423\", \"GLI1\", \"GLI2\", \"HDAC8\", \"SUPT16H\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":{"gene":"ZNF521","tier":"GROUNDING","verdict":"Evidence-grounding concern","subtype":"fabrication","uniprot_band":"medium","rules_fired":"R7","issue":"R7: fabricated (no corpus paper): 28412732"},"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":5,"faith_pct":100.0}}